“We are pleased to collaborate with such a highly respected and successful company. Like us, Vetter is a family-run and well-established service provider,” said Nikolaus Rentschler, chairman, Rentschler Biopharma. “We have known each other for many years and share a commitment to high quality standards and sustainable value creation. Our strategic collaboration is aimed at reducing complexity for our clients, with the joint overarching goal of bringing promising new therapies to patients with serious and rare diseases faster than before.”
Udo Vetter, chairman, Vetter, said, “It is important for businesses to sometimes think outside the box. Pursuing future-oriented and innovative ideas is part of both of our companies’ DNA. The alignment of Rentschler Biopharma’s experience in drug substance manufacturing and our own core competency in drug product pharmaceutical manufacturing is yet another opportunity to pursue.”
The alliance of the two leading CDMOs will leverage Rentschler Biopharma’s extensive experience in drug substance manufacturing, including bioprocess development and API1 production, and Vetter’s strong expertise in aseptic fill and finish and secondary packaging. The companies have already identified opportunities, where early and active exchange of know-how and best-practice will benefit both clients and their drug products. Over the next months, these opportunities will be further validated in pilot client projects with joint teams from both companies.
“We are excited to team up with Vetter to complement our customized development and manufacturing solutions for even the most complex biopharmaceuticals,” said Frank Mathias, chief executive officer, Rentschler Biopharma. “Vetter is adding a wealth of expertise for clinical and commercial drug product supply, well suited to the maturing product pipeline of our clients. Their services are a great fit to our own offering. Our collaboration holds great promise for further simplifying client solutions, while expanding the boundaries of what is possible in biopharmaceutical production.”
Peter Soelkner, managing director, Vetter, said, “There are important synergies between our business portfolios that will provide valuable market foresight that can positively impact our clients’ business and patients’ treatment. Combining our experience enables us to deliver new efficiencies and pathways that streamline the development and the supply chain in ways that address the challenges of complexity companies across the industry are facing.”
Both companies will continue to independently address and service current and new clients as they explore opportunities for cooperative integration of approaches to complex molecules in todays’ rapidly evolving global healthcare environment.